Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas.

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Lymphoproliferative diseases in immunocompromised patients are often linked to herpesviruses.
• Conventional chemotherapy is frequently ineffective for these conditions.
• Previous work showed AIDS-related Burkitt's lymphoma (BL) responded to azidothymidine (AZT) and interferon-alpha (IFN-alpha).

Purpose of the Study:

• To investigate the distinct apoptotic responses of herpesvirus-associated lymphomas to AZT and IFN-alpha.
• To determine factors influencing lymphoma sensitivity or resistance to these antiviral agents.

Main Methods:

• Culturing Epstein-Barr virus (EBV)-positive and EBV-negative lymphoma cells with AZT and/or IFN-alpha.
• Assessing apoptosis, CD95 and CD95 ligand expression, and BCL-2 levels.
• Measuring intracellular AZT monophosphate accumulation.
• Transfecting AZT-sensitive cells with BCL-2.

Main Results:

• EBV-positive BL cells with low BCL-2 underwent apoptosis with AZT alone.
• Primary effusion lymphoma (PEL) cells required IFN-alpha to potentiate AZT-induced apoptosis.
• EBV-negative lymphomas and those with high BCL-2 were resistant to AZT.
• IFN-alpha induced CD95 ligand but not CD95 in BL and PEL.
• AZT-sensitive lymphomas accumulated more AZT monophosphate.

Conclusions:

• Apoptotic responses to AZT and IFN-alpha vary significantly among herpesvirus-associated lymphomas.
• BCL-2 expression levels and viral associations (EBV, HHV-8) dictate therapeutic susceptibility.
• Targeting virus-mediated apoptosis pathways could offer novel therapeutic strategies for these lymphomas.